Guidance
Are rotavirus vaccines a good investment for middle-income countries?
Middle-income countries not eligible for support from Gavi, the Vaccine Alliance, have been slow to introduce rotavirus vaccines, largely due to cost concerns. A PATH analysis shows that, in most cases, rotavirus vaccination is likely to be highly cost-effective and beneficial for these countries.
Authors
Languages
- English
Publication year
2021
Type
Guidance
Categories
- Programme management
Diseases
- Rotavirus
Tags
- Planning, budgeting and financing